its latest version of histological classification of glioma by this knowledge of molecular subtypes. [12] Now, we can make a more precise diagnosis and prognostication for different subtypes of the glioma.
preCision therapeutiCs for other CanCers
This genomic information has already helped to shape the development and use of some of the newest cancer treatments. For example, the drug imatinib was designed to inhibit an altered enzyme produced by a fused version of two genes found in chronic myelogenous leukemia. [13] Another example is the breast cancer drug trastuzumab, which works only for women whose tumors have a particular genetic profile called HER2 positive. [14] Studies have also found that lung cancer patients whose tumors are positive for epidermal growth factor receptor (EGFR) mutations respond to gefitinib and erlotinib -two drugs targeting this mutation. [15, 16] On the other hand, colon cancer patients whose tumors have a mutation in a gene called KRAS derive little benefit from cetuximab and panitumumab. [17] preCision CanCer therapeutiCs for glioma?
The progress in developing effective chemotherapy regimens for primary brain tumors lags behind that of other cancers. Most first-line chemotherapy drugs do not have biomarkers to guide their applications. Molecular classification of most primary brain tumors has identified many potential targets [ Table 1 ]. The type of genomic information should drive research to develop similar treatment strategies for a given set of genomic changes in glioma. Major efforts have been invested in targeting these pathways, but in spite of numerous therapeutic trials, treatment options remain limited and inefficient. There are initial results of case series that shows the dramatic response of recurrent BRAF V600E-mutated glioblastoma to dabrafenib and vemurafenib. [18, 19] The magnitude of the effect is still far from any significance in the major subtypes of glioma and in overall survival data. Basket study design has opened up the opportunity, other than disease-specific studies, for small patient number diseases, i.e., glioma. Basket study requires a molecular profiling platform and collaborations between disciplines and centers for testing the effect of a drug on single mutation in a variety of cancer types. STARTRK-2 trial is an ongoing, multicenter, global phase II basket study of entrectinib (RXDX-101) for the treatment of participants with solid tumors that harbor an NTRK1/2/3, ROS1, or anaplastic lymphoma kinase gene fusion. About 1%-3% of glioblastoma carry the NTRK1 gene fusion. Moreover, 3% of all astrocytomas carry NTRK2 gene fusion. Results from these basket studies will provide more information in precision therapeutics in glioma.
Challenges for preCision CanCer therapeutiCs for glioma
If colon cancer, breast cancer, and lung cancers all have responded to precision cancer therapeutics, what are the factors failing the targeted therapies for glioma?
Tumor heterogeneity
Intratumor heterogeneity, or spatial heterogeneity within tumors, has explained the negative results of many trials. Studies have shown that clonal and subclonal genomic alternations arise early in the tumor growth. Multisector biopsy and sequencing were performed in ten primary glioblastoma. All were treatment-naïve. Hypermutators were found in two samples. After excluding the hypermutators, only 73% of the mutations were clonal and shared among the biopsies taken in different sectors of the same tumor. Subclonal and private mutations were found in 23%. [20] Targeted treatment, even at its best efficacy, would have left out the private mutations which would go dormant until recurrence. Intertumor heterogeneity was also reported that multifocal tumors of glioblastoma sequenced genetically different mutations. [21] The situation is further complicated by the temporal tumor heterogeneity at recurrence. Studies have demonstrated that biopsies taken from the recurrent tumor were genetically distant from the primary tumor (Nei's genetic distance). [21, 22] Cancer genome project has broadened our understanding on the one hand and it has also led us to a larger area of uncertainty of cancer epigenome on the other hand. Mutation events in genetic, epigenetic, transcription factors, and receptors levels have multiplied the complexities of the tumor heterogeneity. [23] Drug screening -personalized cancer therapy Drugs toward actionable target yielded limited success. Studies found that tumors did not simply respond to the class of drugs, i.e., EGFR-driven tumor types. [24] It may respond to a specific drug of the class but not to the others. Thus, we will need tumor models that reflect the true biology and subject the Rb signaling Farnesyltransferase EGFR: Epidermal growth factor receptor, PDGFR: Platelet-derived growth factor receptor, FGFR: Fibroblast growth factor receptor, TGFR: Transforming growth factor receptor, VEGFR: Vascular endothelial growth factor receptor, IGFR: Insulin-like growth factor receptor, VEGF: Vascular endothelial growth factor, MAPK: Mitogen-activated protein kinase, mTOR: Mammalian target of rapamycin, PKC: Protein kinase C, JAK/STAT: Janus kinase/signal transducer and activator of transcription, RB: Retinoblastoma models to drug screening. It will be a high-throughput drug and a combination drug screening to identify potential new therapies. The conventional tumor cell lines are not applicable to its lack of genomic signatures. Transplanting tumors, which retain their widely varying genetic characteristics, into mice to create a panel of tumor-laden mice (patient-derived xenograft [PDX]) are the current direction to address the variability of tumor genomics. However, PDX is not practical for glioma (glioblastoma) model for its prolonged incubation time and the high cost. It would take 4-6 months for the incubation of xenograft before it is suitable for drug testing. This is practically too long for the fast-growing glioblastoma. Allowing drug repositioning, there are over 2000 FDA approved and pipeline drugs available for screening. Single-agent and combination drugs would add up a large number of mice for testing. The high cost would forbid its translation.
Current status of preCision CanCer therapeutiCs for CanCers
So far, large randomized cancer studies of precision cancer therapy have not led to gains in survival. Only 30% to 50% of the patients had suspected driving mutations identified. Moreover, only 3% to 13% had druggable treatment. [25] Combination therapy sounds synergistic in vitro and is attractive clinically. However, drug toxicity and expensive cost have made it clinically unrealistic.
ConClusion
The concept of precision personalized cancer therapy is appealing and is desperately needed to be materialized for glioma. The proposed strategy for precision glioma treatment is to obtain multiple biopsies of patients at the time of surgery within the enhancing and the nonenhancing region of the tumor. Paired samples should always be taken at the time of recurrence for profiling and retreatment. Extensive genome-wide profiling and drug selection are to be individualized. Before a practical high-throughput drug screening platform is available, drugs are carefully chosen and considered with the knowledge about the patient's past treatment history, known molecular profiles, and pharmacokinetics. Drugs that target ubiquitous truncal, as well as private genetic alternations, are the key to success in treatment. Multiple agents are allowed while taking into account of the potential toxicity and safety of using combination therapy. The precision glioblastoma therapy should be materialized in a platform of the well-designed collaborative program, with researches to overcome the above-named challenges.
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